As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Move aligns global biologics identity under the Biocon Biologics brand
Board approves five-year appointment, subject to shareholder nod through postal ballot
The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Subscribe To Our Newsletter & Stay Updated
